Oncolytics Biotech (ONCY) Receivables - Other (2016 - 2025)
Oncolytics Biotech's (ONCY) quarterly Receivables - Other came in at $573000.0 in Q4 2025, up 1077.13% year-on-year from $48677.7 in Q4 2024, and up 1360.31% on a QoQ basis from $39238.3 in Q3 2025.
Oncolytics Biotech (ONCY) Receivables - Other (2016 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has 10 years of Receivables - Other data on file, last reported at $573000.0 in Q4 2025.
- On a quarterly basis, Receivables - Other rose 1077.13% year-over-year to $573000.0 in Q4 2025; TTM through Dec 2025 was $573000.0, a 1077.13% increase from a year earlier, with the FY2025 full-year figure at $573000.0, up 1119.15% from the prior year.
- Receivables - Other for Q4 2025 stood at $573000.0, up from $39238.3 in the prior quarter.
- Over the last five years, Receivables - Other for ONCY reached as high as $1.1 million in Q2 2024 and fell as low as -$65241.8 in Q3 2024.
- Historically, Receivables - Other has averaged $279044.4 across 5 years, with a median of $155086.8 in 2021.
- Across the five-year window, Receivables - Other tumbled 113.88% in 2024 and soared 1077.13% in 2025, its largest moves.
- Year by year, Receivables - Other stood at $687029.0 in 2021, then slumped by 44.13% to $383822.2 in 2022, then sank by 97.13% to $11018.0 in 2023, then surged by 341.8% to $48677.7 in 2024, then surged by 1077.13% to $573000.0 in 2025.
- Per Business Quant data, the three most recent Receivables - Other figures were $573000.0 in Q4 2025, $39238.3 in Q3 2025, and $51963.3 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 573,000.00 |
| Dec 31, 2025 | 573,000.00 |
| Sep 30, 2025 | 39,238.29 |
| Sep 30, 2025 | 39,238.29 |
| Jun 30, 2025 | 51,963.30 |
| Jun 30, 2025 | 51,963.30 |
| Mar 31, 2025 | 62,025.57 |
| Mar 31, 2025 | 62,025.57 |
| Dec 31, 2024 | 48,677.74 |
| Dec 31, 2024 | 48,677.74 |
| Sep 30, 2024 | -65,241.75 |
| Sep 30, 2024 | -65,241.75 |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 75,695.55 |
| Mar 31, 2024 | 75,695.55 |
| Dec 31, 2023 | 11,018.03 |
| Dec 31, 2023 | 11,018.03 |
| Sep 30, 2023 | 469,936.20 |
| Sep 30, 2023 | 469,936.20 |